Plasma <i>p</i> ‐tau217 in relation to mild behavioral impairment: implications for early detection of Alzheimer's disease
Findings add to the evidence base that appropriately measured behavioural symptoms can represent AD proteinopathies, supporting the role of MBI in AD risk stratification. The link between MBI and elevated plasma p-tau217 levels highlights the potential utility of MBI for early AD detection and more efficient clinical trial design by utilizing MBI assessment at screening to identify high-risk individuals for biomarker positivity.
Authors
- Eric Edward Smith (ORCID: https://orcid.org/0000-0003-3956-1668)
- Maryam Ghahremani (ORCID: https://orcid.org/0000-0001-8063-713X)
- Rebeca Leon
- Zahinoor Ismail
Institutions
- University of Calgary (CA)
- Hotchkiss Brain Institute (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_103819
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00